Vurderer å kjøpe aksjene dine @Freddys . Hva legger du de ut for imorgen? 
Kø update.
12.08:
15 Clinical
602 Pharmacy
177 Compliance
12 Likes
Tror man tenger mer tid/data for å kunne konkludere på progresjon.
Ser ut som litt random ja hvor det forsvinner fra
1 Like
Photocure kan synes å være ekstremt heldig med sin partner! Imponerende fremdrift. Og klargjort infrastruktur hvor Asieris også har knyttet til seg Sinopharm. Det er en gigant internasjonalt også.
Ser frem til oppdaring på farten her @aribjo
Tror og håper det går veldig raskt og raskere enn det de største optimistene håper på 
imponert over hva Kina og Asia får til innen biotek og helse.
Med bakteppet 2030 og nærmest rikets sikkerhet hva gjelder befolkning og demografi **
er det ikke tid til såkalt avvente.
“Healthy China 2030” (HC2030) is a national strategy aiming to improve the health and well-being of the Chinese population by 2030. It emphasizes a holistic approach, focusing on prevention, treatment, and creating a healthy environment. The initiative promotes healthy lifestyles, optimizes healthcare services, and develops a robust health industry.
Key aspects of HC2030:
- Health Priority: Placing health at the forefront of national development and public policy.
- Innovation: Encouraging innovation in healthcare and the health industry.
- Scientific Development: Balancing prevention and treatment, emphasizing Chinese and Western medicine.
- Fairness and Justice: Ensuring equitable access to healthcare services, especially in rural areas.
- Five Strategies: Popularizing healthy lifestyles, optimizing healthcare services, improving health protection, building a healthy environment, and developing a healthy industry.
- Specific Targets: Including increasing life expectancy to 79 years, improving health literacy, and controlling major risk factors.
- Cross-cutting Measures: Implementing measures related to tobacco control, nutrition, and physical activity.
- Public Health Security: Strengthening the public health security system and promoting health science and technology innovation.
- Industry Development: Fostering a strong health industry with innovative and internationally competitive enterprises.
- Global Impact: Contributing to global health through knowledge sharing and best practices, according to Johnson & Johnson.
HC2030 is designed to be a comprehensive and integrated approach to improving the health of the Chinese population, with far-reaching implications for public health globally.
Fruktbarhet kan nok bli særlig prioritert.
China aims to eliminate cervical cancer by 2030, aligning with the World Health Organization’s (WHO) global strategy, which includes achieving 90% HPV vaccination coverage among girls by age 15, along with increased screening and treatment targets. While China has made progress in cervical cancer prevention, challenges remain in HPV vaccine coverage and screening rates.
Key aspects of China’s cervical cancer elimination strategy:
- HPV Vaccination:
The WHO set a global target of 90% HPV vaccination coverage for girls by age 15 by 2030.
The WHO target also includes screening 70% of women aged 35 and again at age 45 using high-performance tests.
- Treatment:
The WHO target includes providing treatment for 90% of women with cervical cancer or precancerous lesions.
- China’s Targets:
China has incorporated these goals into national plans, including the “Action Plan to Accelerate the Elimination of Cervical Cancer in China (2023-2030)”.
- National Immunization Program (NIP):
Despite the importance of HPV vaccination, it has not yet been included in China’s NIP.
- Pilot Programs:
Some regions and cities in China are initiating pilot programs to provide free HPV vaccination for school-aged girls through subsidies and health insurance.
Challenges and Considerations:
- Low HPV Vaccination Coverage:
China’s HPV vaccination coverage remains low compared to other countries.
- Parental Attitudes:
Parental attitudes and perceptions towards the vaccine significantly influence vaccination rates.
- Screening Rates:
Cervical screening rates are also below the WHO targets, particularly in some regions.
- Cost:
The cost of HPV vaccines and screening tests can be a barrier for some individuals and families.
- Implementation Gaps:
There are gaps in the implementation of screening and treatment programs, especially in resource-limited areas.
Moving Forward:
- Government Support:
China’s government is encouraging more regions to explore ways to support free HPV vaccination for girls.
- Research and Development:
Research is ongoing to assess the cost-effectiveness of different HPV vaccination strategies and to develop more effective and accessible screening and treatment methods.
- Public Awareness:
Raising public awareness about the importance of HPV vaccination and cervical cancer screening is crucial.
- Addressing Barriers:
Efforts are needed to address barriers to vaccination, such as cost, accessibility, and parental concerns.
- Strengthening Healthcare Infrastructure:
Improving healthcare infrastructure and access to screening and treatment services is essential.
3 Likes
Så nå er det nye lister på 600+ foran PHO det skal følges med på? Hjelpes.
Hva var det Dan-the-man sa? Sent 25 tidlig 26.
Bare å avvente.
Hvis man ikke finner glede med å følge med på et og annet, så er vel strengt tatt ikke aksjer det mest innlysende å drive med.
4 Likes
Typ 300 av de 600 er pauset/inaktive. Om man antar en fremgang på ~7-10 plasser om dagen (frekvens hittil - kan plutselig hoppe/øke) er det da «maks» snakk om 30-40 dager. Det gikk meget raskt tidlig på nyåret, og dette burde vel gå enda raskere (siste runde).
2 Likes
Lov å spørre hvorfor noen er pauset/inaktive?
Vet ikke, var flere slike i listene der vi fulgte fremdrift sist også.
Mhm, så er jo spørsmålet, kan slikt inntreffe for Cevira sin del 
Noen som vett årsak, til hvorfor enkelte søknader blir pauset/inaktive?
Haha, tenkte samme tanken akkurat jeg også…
Alt er vel mulig, men sliter med å anse det som sannsynlig.
Hvilket valg er dette? Får ikke samme resultat som deg. Ser fortsatt ut som pharmacy er 602, som nevnt 1208.
Tickerbox “comprehensive” er valgt, og ikke “major”. Da vil man få det slik som hans screenshot viser.
Er vel forsåvidt en måte å se på køa det og regner jeg med. “Alle underkategorier samlet i en kø”?
1 Like
Gør det vel lidt mere vanskeligt at gennemskue status på afgørelse – eller ??
Fin stigning i dag Asireis 
DK
2 Likes
Har ikke fulgt med på den køen der, men vi kan no merke oss tallet fra screenshot til Mrkarl1 idag og se i slutten av uken hva tallet er da.
1 Like